Phil Revenue and Competitors

Location

$121.6M

Total Funding

Estimated Revenue & Valuation

  • Phil's estimated annual revenue is currently $29M per year.(i)
  • Phil received $10.0M in venture funding in August 2017.
  • Phil's estimated revenue per employee is $150,500
  • Phil's total funding is $121.6M.

Employee Data

  • Phil has 193 Employees.(i)
  • Phil grew their employee count by 12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$203M1014-20%$65MN/A
#2
$33.4M2172%N/AN/A
#3
$45M299-4%$102.6MN/A
#4
$3.2M30-25%$21.3MN/A
#5
$34M2260%$42.9MN/A
#6
$3.6M34-28%$35MN/A
#7
$0.8M10N/AN/AN/A
#8
$12.6M90-9%N/AN/A
#9
$17.4M1240%$96.4MN/A
#10
$7.9M6518%$75.6MN/A
Add Company

Phil is a service that matches folks taking recurring medications with top-rated, community-based pharmacies that manage and deliver prescriptions on time, at no extra cost and take on the task of navigating doctors and insurance.

keywords:Healthcare, Health Care Information Technology

$121.6M

Total Funding

193

Number of Employees

$29M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Phil News

2022-04-20 - Liverpool vs Man Utd: Phil Jones starts for the visitors in surprise back three at Anfield

Phil Jones has been included in Man United's starting lineup for their clash with Liverpool. United have made the trip to Merseyside on...

2022-04-20 - Roy Keane shares brutal Phil Jones assessment after Manchester United decision vs Liverpool

Manchester United made four changes for the Liverpool game with Phil Jones handed a rare start.

2022-04-20 - Phil Jones should have been digging Ralf Rangnick out at half-time of Liverpool loss, insists O'Hara

The defender was handed just his second start of the season at Anfield following a formation change to a five-man defence by German boss...

2021-09-30 - Impel NeuroPharma : Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine

SAN FRANCISCO, Sept. 29, 2021 /PRNewswire/ -- Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil's ...

2021-06-07 - Phil Raises $56M in Series D Funding

Phil, a San Francisco, CA-based provider of therapy deployment software for the pharma market, raised $56M in Series D funding. The round is part of an arrangement for Warburg Pincus to invest up to $100 million. As part of the deal, Fred Hassan, Director at Warburg Pincus, will join Phil’s boa ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$73.2M1932%$40M
#2
N/A19311%N/A
#3
$29.7M193N/AN/A
#4
$27.3M19314%N/A
#5
$27.6M19325%N/A

Phil Funding

DateAmountRoundLead InvestorsReference
2017-08-17$10.0MUndisclosedCrosslink CapitalArticle